Monograph Details
|
|
Neoplasms
> Antimetabolites
|
|
CLOLAR |
| Manufacturer |
|
Genzyme Corporation |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Purine nucleoside antimetabolite. |
| Generic Name |
|
Clofarabine 1mg/mL; soln for IV infusion after dilution; preservative-free. |
| Indications |
|
Acute lymphoblastic leukemia (ALL) in patients 1–21 years of age after relapses from, and/or refractoriness to, at least two prior regimens. |
| Children |
|
Obtain baseline and monitor hematological, renal, and hepatic function before and during therapy. Monitor vital signs during infusion. Give by IV infusion over 2 hours. 1–21yrs: 52mg/m2 daily for 5 consecutive days; repeat approximately every 2 to 6 weeks following recovery or return to baseline organ function. Give IV fluids continuously during treatment. May give corticosteroids or allopurinol prophylactically. |
| Adults |
|
>21yrs: consult manufacturer. |
| Precautions |
|
Monitor for signs/symptoms of infection, tumor lysis syndrome, cytokine release (eg, tachypnea, hypotension); discontinue if cytokine release progresses to systemic inflammatory response syndrome (SIRS)/capillary leak syndrome and/or if organ dysfunction (grade 3 or 4 hepatic or renal toxicity) occurs; may restart at lower dose if organ function recovers and patient is stable. Ensure adequate hydration. Pregnancy (Cat.D); use effective contraception. Nursing mothers: not recommended. |
| Interactions |
|
Avoid renal or hepatic toxic drugs during administration. Caution with drugs that affect BP or cardiac function. |
| Adverse Reactions |
|
Bone marrow suppression/hematological toxicity (eg, febrile neutropenia, anemia, leukopenia, thrombocytopenia), infections, GI upset, tachycardia, pain, fever, anorexia, respiratory distress, dermatitis, hypotension; elevated ALT/AST, bilirubin, and creatinine. |
| How Supplied |
|
Single-use vial (20mL)—1, 4 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
